Procter & Gamble heads into its July 28 quarterly report having given back the $150 recovery celebrated just days ago, with options positioning now the calmest it has been all cycle.
The stock closed at $147.41 on July 24, down 1.7% on the week and 2.3% over the past month. That reversal unwound the gains flagged in last week's report, when P&G briefly reclaimed $150 on the back of call-heavy options flow. That call skew has since faded. The put/call ratio sits at 0.617 — roughly 1.2 standard deviations below its 20-day mean of 0.687. Ordinarily a bullish read, the context matters: the PCR swung from its 52-week high of 1.106 in mid-June to its 52-week low of 0.535 weeks later, and has now settled into a calmer middle ground rather than a conviction signal in either direction. With the borrow market entirely unthreatening — availability is at the maximum reading, cost to borrow is just 0.33%, and short interest is a structurally irrelevant 1.05% of float — there is no pressure from the lending side of the market.
Analyst direction into the print has been a mild drift lower. Barclays raised its target to $152 from $146 this week while holding an Equal-Weight rating — a modest tweak that still implies only 3% upside from current levels. JPMorgan trimmed its target to $162 from $164 earlier in July, keeping its Overweight. Bank of America also cut to $166 from $170 while staying at Buy. The pattern is consistent: bellwether firms still lean positive but are paring back targets ahead of the report, with the consensus mean now at $163.61, representing roughly 11% upside to the current price. Bulls point to the 5% sales growth delivered in early 2026, improving market share, and positive momentum building in Europe and Latin America. Bears focus on the 30% collapse in SK-II brand sales in Greater China and the 15% drop in U.S. category growth rates in December — data points that point to structural weakness in two of the company's most important regions. Note that the Benzinga bull/bear case data carries a late-2025 timestamp, so some of those specific figures may be dated relative to the upcoming print.
The peer group has moved in the same direction this week, but P&G has held up better than several close comparisons. Clorox fell nearly 5% on the week and Colgate-Palmolive dropped 4.2%, against P&G's 1.7% decline. That relative resilience is consistent with P&G's historically lower volatility profile — its last two earnings prints produced gains of 1.8% and 2.8% in the session following results, with five-day moves in the same direction, suggesting the stock has rewarded near-term holders on recent reports.
The July 28 print will test whether the combination of geographic headwinds in China and softening U.S. consumer trends is already priced into a stock trading at 20x earnings, or whether P&G's volume recovery and share-gain narrative can justify a rerating back toward the $163 analyst consensus.
See the live data behind this article on ORTEX.
Open PG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
